Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans
Key Points
Prior authorization for semaglutide and tirzepatide is common in Medicare Part D plans, impacting patient access.
The study highlights disparities in coverage trends for glucagon-like peptide-1 receptor agonists among beneficiaries.
Analysis indicates a significant variation in prior authorization requirements, which may complicate treatment options.
Medicare Part D policies for these medications reveal important implications for managing chronic diseases.
Abstract
This cross-sectional study examines trends in coverage of glucagon-like peptide-1 receptor agonists, semaglutide and tirzepatide, and prior authorization requirements among Medicare Part D beneficiaries.